Literature DB >> 25837542

Technical performance score as predictor for post-discharge reintervention in valve-sparing tetralogy of Fallot repair.

Meena Nathan1, Audrey C Marshall2, Jason Kerstein3, Hua Liu3, Francis Fynn-Thompson3, Christopher W Baird3, John E Mayer3, Frank A Pigula3, Pedro J del Nido3, Sitaram Emani3.   

Abstract

Recognition of late problems following repair of tetralogy of Fallot (TOF) with a transannular patch has stimulated modifications to preserve pulmonary valve (PV) function. This study assesses the ability of technical performance score (TPS) to determine the need for post-discharge reinterventions (RIs) in valve-sparing TOF repair. We retrospectively reviewed 157 patients following valve-sparing repair of TOF from 2007-2012. We assigned TPS as Class 1 (optimal), Class 2 (adequate), or Class 3 (inadequate) based on discharge echo and clinical criteria. Preoperative, discharge, and follow-up PV Z scores and post-discharge RIs were documented. Reasons for Class 2 or 3 designation were right ventricular outflow tract (RVOT) gradient in 52, pulmonary regurgitation in 13, residual ventricular septal defects in 7, both RVOT gradient and ventricular septal defects in 13, and both RVOT gradient and pulmonary regurgitation in 37 patients. Median follow-up was 19.6 (range: 0.1-86.1) months. Class 3 patients had a significantly longer median intensive care unit and hospital stay compared with Class 1 (3 vs 2 days [P = 0.015] and 7 vs 5 days [P < 0.001], respectively). Post-discharge RIs were significantly lower in Class 1 vs Class 2 and Class 3 (P = 0.003). Class 1 patients had significantly larger PV Z scores compared with Class 2 or Class 3 patients (P < 0.001). TPS is associated with post-discharge RI rate after valve-sparing TOF repair. Preoperative PV Z score is highly correlated with Class I TPS. Patient selection based on preoperative PV Z scores may help determine if valve-sparing approach is appropriate, thus minimizing the need for RIs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  congenital cardiac surgery; outcomes; pulmonary stenosis; technical performance score; tetralogy of Fallot; valve sparing repair

Mesh:

Year:  2014        PMID: 25837542     DOI: 10.1053/j.semtcvs.2014.12.001

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

1.  The Pediatric Heart Network Residual Lesion Score Study: Design and objectives.

Authors:  Meena Nathan; Felicia L Trachtenberg; Maria I Van Rompay; William Gaynor; Kirk Kanter; Richard Ohye; Emile A Bacha; James Tweddell; Steven M Schwartz; L LuAnn Minich; Carlos M Mery; Steven D Colan; Jami Levine; Linda M Lambert; Jane W Newburger
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-15       Impact factor: 5.209

2.  Impact of Major Residual Lesions on Outcomes After Surgery for Congenital Heart Disease.

Authors:  Meena Nathan; Jami C Levine; Maria I Van Rompay; Linda M Lambert; Felicia L Trachtenberg; Steven D Colan; Iki Adachi; Brett R Anderson; Emile A Bacha; Aaron Eckhauser; J William Gaynor; Eric M Graham; Benjamin Goot; Jeffrey P Jacobs; Rija John; Jonathan R Kaltman; Kirk R Kanter; Carlos M Mery; L LuAnn Minich; Richard Ohye; David Overman; Christian Pizarro; Geetha Raghuveer; Marcus S Schamberger; Steven M Schwartz; Shanthi L Narasimhan; Michael D Taylor; Ke Wang; Jane W Newburger
Journal:  J Am Coll Cardiol       Date:  2021-05-18       Impact factor: 24.094

3.  A Long-Term Survivor with Tetralogy of Fallot Treated Only with the Classical Blalock-Taussig Shunt.

Authors:  Yu Yamada; Tomoko Ishizu; Hidekazu Tsuneoka; Yutaka Eki; Hitoshi Horigome
Journal:  Case Rep Cardiol       Date:  2018-08-19

4.  Application of the Boston Technical Performance Score to intraoperative echocardiography.

Authors:  Hannah R Bellsham-Revell; Antigoni Deri; Silvia Caroli; Andrew Durward; Owen I Miller; Sujeev Mathur; Jelena Saundankar; David R Anderson; B Conal Austin; Caner Salih; Kuberan Pushparajah; John M Simpson
Journal:  Echo Res Pract       Date:  2019-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.